KR102826089B1 - 활성 알파 시누클레인에 결합하는 항체 - Google Patents

활성 알파 시누클레인에 결합하는 항체 Download PDF

Info

Publication number
KR102826089B1
KR102826089B1 KR1020207003980A KR20207003980A KR102826089B1 KR 102826089 B1 KR102826089 B1 KR 102826089B1 KR 1020207003980 A KR1020207003980 A KR 1020207003980A KR 20207003980 A KR20207003980 A KR 20207003980A KR 102826089 B1 KR102826089 B1 KR 102826089B1
Authority
KR
South Korea
Prior art keywords
synuclein
antibody
active
sample
aggregates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207003980A
Other languages
English (en)
Korean (ko)
Other versions
KR20200033880A (ko
Inventor
아리엘 루리에
Original Assignee
스트레스마크 바이오사이언시즈 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스트레스마크 바이오사이언시즈 인코퍼레이티드 filed Critical 스트레스마크 바이오사이언시즈 인코퍼레이티드
Publication of KR20200033880A publication Critical patent/KR20200033880A/ko
Application granted granted Critical
Publication of KR102826089B1 publication Critical patent/KR102826089B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR1020207003980A 2017-08-02 2018-08-02 활성 알파 시누클레인에 결합하는 항체 Active KR102826089B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762540435P 2017-08-02 2017-08-02
US62/540,435 2017-08-02
PCT/CA2018/050952 WO2019023809A1 (en) 2017-08-02 2018-08-02 ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEINE

Publications (2)

Publication Number Publication Date
KR20200033880A KR20200033880A (ko) 2020-03-30
KR102826089B1 true KR102826089B1 (ko) 2025-06-30

Family

ID=65232133

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207003980A Active KR102826089B1 (ko) 2017-08-02 2018-08-02 활성 알파 시누클레인에 결합하는 항체

Country Status (10)

Country Link
US (2) US11098108B2 (https=)
EP (1) EP3661961A4 (https=)
JP (1) JP7204235B2 (https=)
KR (1) KR102826089B1 (https=)
CN (1) CN111225923B (https=)
AU (1) AU2018312441B2 (https=)
BR (1) BR112020001970A2 (https=)
IL (1) IL272361B2 (https=)
SA (1) SA520411188B1 (https=)
WO (1) WO2019023809A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
BR112019013953A2 (pt) 2017-01-06 2020-02-11 Abl Bio Inc. Anticorpo anti-a-syn e uso do mesmo
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
EP3618870A4 (en) 2017-05-01 2021-04-21 The Trustees of The University of Pennsylvania MONOCLONAL ANTIBODIES AGAINST ALPHA-SYNUCLEIN FIBRILLES
EP3661961A4 (en) 2017-08-02 2021-04-14 Stressmarq Biosciences Inc. ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN
EP3725806A4 (en) 2017-12-14 2022-03-30 ABL Bio Inc. BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE
EP4268842A3 (en) * 2019-06-14 2024-05-22 ABL Bio, Inc. BISPECIFIC ANTIBODY AGAINST a-SYN/IGF1R AND USE THEREOF
US20230025707A1 (en) * 2019-11-19 2023-01-26 The Trustees Of The University Of Pennsylvania Anti-Alpha-Synuclein Monoclonal Antibodies, and Methods Using Same
NL2025332B1 (en) 2020-04-10 2021-10-26 Syngle Therapeutics B V Novel alpha-synuclein binding antibodies, or antigen binding portions thereof.
KR102505164B1 (ko) * 2020-09-29 2023-02-28 서울대학교산학협력단 신경퇴행성 질환의 예방 또는 치료용 펩타이드 및 이를 포함하는 약학 조성물
CN113912713B (zh) * 2021-12-15 2022-03-08 北京凯祥弘康生物科技有限公司 一种抗α-突触核蛋白的单克隆抗体及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3823313A1 (de) 1988-07-09 1990-01-11 Henkel Kgaa Fussbodenreinigungsgeraet
US20040143093A1 (en) 2002-07-11 2004-07-22 Ralph Zahn Method for inducing a conformational transition in proteins, such as pathogenic/infectious proteins, and their use
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
PT2282758T (pt) 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
WO2009152607A1 (en) * 2008-06-16 2009-12-23 Ottawa Hospital Research Institute Methods and kits for diagnosing neurodegenerative disease
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
JP5894939B2 (ja) * 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
CA2840224C (en) 2011-06-22 2019-08-13 The General Hospital Corporation Treatment of proteinopathies
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
DK2807188T3 (da) * 2012-01-27 2019-10-07 Prothena Biosciences Ltd Humaniserede antistoffer, der genkender alpha-synuclein
EP3594240B1 (en) 2013-05-20 2023-12-06 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
LT3071597T (lt) * 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
DK3114141T3 (da) 2014-03-06 2020-08-10 Nat Res Council Canada Insulinlignende vækstfaktor 1-receptor-specifikke antistoffer og anvendelse deraf
PE20170088A1 (es) 2014-03-06 2017-03-09 Nat Res Council Canada Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
NZ724869A (en) 2014-03-06 2022-07-01 Nat Res Council Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
CN103983778B (zh) * 2014-05-08 2016-04-13 首都医科大学宣武医院 一种检测受实验者体液体外促进疾病相关蛋白聚合能力的方法
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP3661961A4 (en) 2017-08-02 2021-04-14 Stressmarq Biosciences Inc. ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN

Also Published As

Publication number Publication date
CN111225923A (zh) 2020-06-02
EP3661961A1 (en) 2020-06-10
JP7204235B2 (ja) 2023-01-16
AU2018312441A1 (en) 2020-02-06
IL272361A (en) 2020-03-31
KR20200033880A (ko) 2020-03-30
JP2020529473A (ja) 2020-10-08
US20210139569A1 (en) 2021-05-13
US11919947B2 (en) 2024-03-05
BR112020001970A2 (pt) 2020-08-04
IL272361B1 (en) 2025-02-01
WO2019023809A1 (en) 2019-02-07
EP3661961A4 (en) 2021-04-14
CN111225923B (zh) 2024-09-24
US11098108B2 (en) 2021-08-24
IL272361B2 (en) 2025-06-01
SA520411188B1 (ar) 2023-01-08
US20210355202A1 (en) 2021-11-18
AU2018312441B2 (en) 2024-10-17
CA3071634A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
KR102826089B1 (ko) 활성 알파 시누클레인에 결합하는 항체
US10040847B2 (en) Methods of treating a tauopathy
JP6446443B2 (ja) タウオパチーの処置方法
US9895429B2 (en) Antibodies that bind amyloid oligomers
US20130084283A1 (en) Oligomer-specific amyloid beta epitope and antibodies
CN109937210A (zh) 用于治疗共核蛋白病的药剂、用途和方法
TWI908724B (zh) TrkA的抗體及其應用
KR20200026789A (ko) 시누클레인병증을 치료하기 위한 조성물 및 방법
US20160122421A1 (en) Methods of treating a tauopathy
CA3071634C (en) Antibody binding active alpha-synuclein
HK1208175B (en) Methods of treating a tauopathy
HK1185350B (en) Oligomer-specific amyloid beta epitope and antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200211

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210714

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240806

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250523

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250624

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250625

End annual number: 3

Start annual number: 1

PG1601 Publication of registration